We are proud to present that Biocytogen will be attending the SITC 2025 Annual Meeting from November 7th-8th in National Harbor, Maryland! This conference brings together leading experts to highlight cutting-edge research, clinical advancements, and collaborative strategies aimed at improving patient care. Through keynote presentations, plenary and rapid oral abstract sessions, poster receptions, and an engaging symposium, SITC 2025 promotes education, meaningful networking, and the translation of scientific discoveries into real-world outcomes. Join us at booth #414 to meet the team and learn more about our scientific breakthroughs and cutting-edge technologies. We hope to see you there.
What is the SITC 2025 Annual Meeting?
The SITC(Society for Immunotherapy of Cancer) marks its 40th anniversary of discovering breakthroughs in cancer immunotherapy. This conference unites top-tier experts to showcase groundbreaking research, clinical breakthroughs, and collaborative pathways to improve patient outcomes.From Keynotes, planetary and rapid oral abstract sessions, poster receptions and an insightful symposium, SITC 2025 fosters education, networking, and translational research, from foundational science to real-world impact
Event Overview
Date: November 7th - 8th, 2025 | 7:45 a.m.–7:00 p.m. ET
Venue: Gaylord National Resort and Convention Center. 201 Waterfront Street, National Harbor, MD 20745
Event Schedule
For more information, please refer to SITC 2025 Annual Meeting Schedule
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We can’t wait to see you in Maryland for the SITC Annual Meeting!
